Histone deacetylase inhibitors: Are they here to stay?

Ibrahim, Rami B.
May 2010
American Journal of Health-System Pharmacy;5/15/2010, Vol. 67 Issue 10, p791
Academic Journal
The author discusses the histone deacetylase (HDAC) which is approved by the U.S. Food and Drug Administration. It informs that HDAC inhibitors proved to be beneficial in antitumor activity and cancer-free survival. It concludes that HDAC inhibitors are having a positive impact on the results of patients with cancer.


Related Articles

  • METHYLGENE TO RESUME DEVELOPMENT OF MGCD0103 (MOCETINOSTAT).  // Worldwide Biotech;Nov2009, Vol. 21 Issue 11, p3 

    The article reports that the Food and Drug Administration (FDA) in the U.S. has removed the partial clinical hold placed on MGCD0103, the proprietary selective histone deacetylase (HDAC) inhibitor for cancer from MethylGene Inc. The company is expected to restart enrollment of patients in its...

  • Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration. Sleiman, Sama F.; Berlin, Jill; Basso, Manuela; Karuppagounder, Saravanan S.; Rohr, Jürgen; Ratan, Rajiv R. // Pharmaceuticals (14248247);Aug2011, Vol. 4 Issue 8, p1183 

    Mithramycin A (MTM) and histone deacetylase inhibitors (HDACi) are effective therapeutic agents for cancer and neurodegenerative diseases. MTM is a FDA approved aureolic acid-type antibiotic that binds to GC-rich DNA sequences and interferes with Sp1 transcription factor binding to its target...

  • Histone Deacetylase Inhibitors and Anticancer Therapy. G. Kouraklis; S. Theocharis // Current Medicinal Chemistry - Anti-Cancer Agents;Jul2002, Vol. 2 Issue 4, p477 

    Recent reports have shown that pharmacological manipulation of chromatin remodeling by histone deacetylase (HDAC) inhibitors, might develop into a potent and specific strategy for the treatment of cancer. Alterations in histone acetylation may lead to changes in chromatin structure and...

  • HDAC inhibitors overcome first hurdle. Garber, Ken // Nature Biotechnology;Jan2007, Vol. 25 Issue 1, p17 

    The article reports on the different aspects relating to approval of the drug histone deacetylase (HDAC) inhibitor by U.S. Food and Drug Administration (FDA). Though there is little clinical evidence on the effect of the drug in treating different types of cancers, the drug was approved by the...

  • Epigenetic Therapy for Breast Cancer. Feng-Feng Cai; Kohler, Corina; Bei Zhang; Ming-Hong Wang; Wei-Jie Chen; Xiao-Yan Zhong // International Journal of Molecular Sciences;Jul2011, Vol. 12 Issue 7, p4465 

    Both genetic and epigenetic alterations can control the progression of cancer. Genetic alterations are impossible to reverse, while epigenetic alterations are reversible. This advantage suggests that epigenetic modifications should be preferred in therapy applications. DNA methyltransferases and...

  • FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. Mann, Bhupinder S.; Johnson, John R.; Cohen, Martin H.; Justice, Robert; Pazdur, Richard // Oncologist;Oct2007, Vol. 12 Issue 10, p1248 

    On October 6, 2006, the U.S. Food and Drug Administration granted regular approval to vorinostat (Zolinza®; Merck & Co., Inc., Whitehouse Station, NJ), a histone deacetylase inhibitor, for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with...

  • FDA Approves Iressa for Advanced Lung Cancer. Wang, Linda // JNCI: Journal of the National Cancer Institute;6/4/2003, Vol. 95 Issue 11, p777 

    Reports that the U.S. Food and Drug Administration approved the drug Iressa, an epidermal growth factor receptor inhibitor, as a treatment for patients with advanced non-small cell lung cancer (NSCLC) who exhausted all other treatment options. Australian Therapeutic Goods Administration's...

  • Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity. Lech-Maranda, Ewa; Robak, Ewa; Korycka, Anna; Robak, Tadeusz // Mini Reviews in Medicinal Chemistry;Oct2007, Vol. 7 Issue 10, p1062 

    Depsipeptide (FK228), a new histone deacetylase inhibitor, has been recently introduced into clinical trials. This agent shows interesting metabolic properties, novel mechanism of action, and is undergoing phase I-II clinical studies in hematopoietic malignancies and solid tumors. Mechanism of...

  • Histone deacetylase inhibitors for treatment of hepatocellular carcinoma. Corandini, Danila; Speranza, Annalisa // Acta Pharmacologica Sinica;Sep2005, Vol. 26 Issue 9, p1025 

    Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. Surgical resection has been considered the optimal treatment approach, but only a small proportion of patients are suitable candidates for surgery, and the relapse rate is high. Approaches to prevent recurrence,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics